// App-Quantinova.ai

SUN-88 : Inhibition of GH and IGF-1 Is Maintained with Pasireotide LAR and Octreotide LAR in Patients with Acromegaly: 12-Month Extension Phase of a Double-Blind, Multicenter, Randomized, Phase III Study

Researchers

Presenter

  • Marcello D Bronstein

Principal Investigators

  • Pamela U Freda

  • Omar Serri

  • Laura De Marinis

  • Luciana Ansaneli Naves

  • Liudmila Rozhinskaya

  • Karina Hermosillo Resendiz

  • Matthieu Ruffin

  • Kobby Asubonteng

  • Annamaria Colao

Medical Centers

  • University of Sao Paulo Medical School, Sao Paulo, Brazil

  • National Endocrinology Research Centre, Moscow, Russia

  • Notre-Dame Hospital, University of Montreal, Montreal, Canada

  • Universita Cattolica del Sacro Cuore, Rome, Italy

  • Columbia Univ Coll of Physicians and Surgeons, New York, NY

  • Universita Federico II di Napoli, Napoli, Italy

  • University of Birmingham, Birmingham, United Kingdom

  • Universidade de Brasilia, Brasilia, Brazil

Locations

  • Brazil

  • Canada

  • Italy

  • United Kingdom

  • United States

  • Russia

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Diabetes

  • Gallbladder disease

  • Hyperglycemia

  • Acromegaly

Biomarkers

  • Protein Tyrosine Phosphatase, Receptor Type F

  • Cytochrome P450 Family 51

  • Insulin-like growth factor 1

Drug/Treatment

  • Pasireotide

  • Octreotide

  • Mecasermin

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved